MUC1 and neoplasm: Vaccines targeting oligosaccharylated MUC1 are being developed to induce antibodies and T cells to eliminate inflammatory and/or tumor-initiating cells expressing this form of MUC1, thereby preventing further inflammation promoting the anti-tumor activity of many effector cells in the microenvironment [47].